PL4321175T3 - Magnetyczne nanokapsuły polimerowe nadające się do stosowania w terapii, zwłaszcza antynowotworowej - Google Patents
Magnetyczne nanokapsuły polimerowe nadające się do stosowania w terapii, zwłaszcza antynowotworowejInfo
- Publication number
- PL4321175T3 PL4321175T3 PL22461593.0T PL22461593T PL4321175T3 PL 4321175 T3 PL4321175 T3 PL 4321175T3 PL 22461593 T PL22461593 T PL 22461593T PL 4321175 T3 PL4321175 T3 PL 4321175T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- therapy
- ones
- magnetic polymer
- especially anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22461593.0A EP4321175B1 (en) | 2022-08-11 | 2022-08-11 | Magnetic polymer nanocapsules suitable for use in therapy, especially anti-cancer ones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4321175T3 true PL4321175T3 (pl) | 2025-12-22 |
Family
ID=83598584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22461593.0T PL4321175T3 (pl) | 2022-08-11 | 2022-08-11 | Magnetyczne nanokapsuły polimerowe nadające się do stosowania w terapii, zwłaszcza antynowotworowej |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4321175B1 (pl) |
| JP (1) | JP2025527328A (pl) |
| KR (1) | KR20250065609A (pl) |
| CN (1) | CN120475993A (pl) |
| CA (1) | CA3264708A1 (pl) |
| PL (1) | PL4321175T3 (pl) |
| WO (1) | WO2024033546A1 (pl) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI538701B (zh) | 2015-01-13 | 2016-06-21 | 國立清華大學 | 用於藥物傳遞的蛋白質奈米磁性殼核膠囊及其應用 |
| PL229276B1 (pl) | 2015-07-17 | 2018-06-29 | Univ Jagiellonski | Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania |
| PL240632B1 (pl) | 2018-04-06 | 2022-05-09 | Univ Jagiellonski | Zastosowanie nanokapsuły z ciekłym rdzeniem olejowym w terapii przeciwnowotworowej |
-
2022
- 2022-08-11 PL PL22461593.0T patent/PL4321175T3/pl unknown
- 2022-08-11 EP EP22461593.0A patent/EP4321175B1/en active Active
-
2023
- 2023-08-11 CN CN202380072570.9A patent/CN120475993A/zh active Pending
- 2023-08-11 WO PCT/EP2023/072350 patent/WO2024033546A1/en not_active Ceased
- 2023-08-11 KR KR1020257008003A patent/KR20250065609A/ko active Pending
- 2023-08-11 CA CA3264708A patent/CA3264708A1/en active Pending
- 2023-08-11 JP JP2025507629A patent/JP2025527328A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3264708A1 (en) | 2024-02-15 |
| WO2024033546A1 (en) | 2024-02-15 |
| EP4321175B1 (en) | 2025-07-16 |
| KR20250065609A (ko) | 2025-05-13 |
| CN120475993A (zh) | 2025-08-12 |
| JP2025527328A (ja) | 2025-08-20 |
| EP4321175A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mirzaei et al. | Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy | |
| CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
| MX378635B (es) | Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia. | |
| EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
| EP4461308A3 (en) | Toxicity management for anti-tumor activity of cars | |
| PL3069728T3 (pl) | Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu | |
| WO2009156117A3 (de) | Vorrichtung zur magnetfeldtherapie | |
| WO2012086991A3 (ko) | 광 치료장치 및 이의 제어방법 | |
| WO2013120038A3 (en) | Morpholino targeting dux4 for treating fshd | |
| MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
| ES2723827T3 (es) | Terapia de combinación de fármacos para el tratamiento de tumores sólidos | |
| MY173310A (en) | Cationic polymers for treating construction aggregates | |
| EP4268900A3 (en) | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment | |
| WO2015112850A3 (en) | Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders | |
| LT3917538T (lt) | Deoksi-citidino dariniai, skirti panaudoti vėžio terapijose | |
| WO2011011061A3 (en) | Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy | |
| WO2011017096A3 (en) | Methods of treating hematologic cancers | |
| BR112013019674A2 (pt) | método para remoção de metoxipirazinas de vinho e/ou suco, para a remoção de compostos indesejáveis no vinho e/ou suco, para a modificação do perfil organoléptico de vinho e/ou suco e para a remoção de um composto-alvo de vinho e/ou suco | |
| EA201200190A1 (ru) | Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы | |
| WO2005123908A3 (en) | Novel cancer cell lines and uses thereof | |
| GB201202600D0 (en) | Machine for flash-butt welding of rails | |
| EP4043583A4 (en) | BIOMARKERS, METHODS, KIT AND ARRAY FOR PREDICTING THERAPEUTIC EFFECTS OF BCG-INTRAVESIC INFUSION THERAPY FOR TREATING BLADDER CANCER | |
| EP4349410A3 (en) | A composition for use in the therapeutic treatment of a cancer or a tumor | |
| WO2008108647A3 (en) | Enhancement of anticancer therapy by flavonoids | |
| MX2012007797A (es) | Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. |